Newsroom

News from our partners

 This newsroom will share the latest information about anything related to narcolepsy, idiopathic hypersomnia, and sleep together with press releases from us and our partners.

02/21/24
Harmony Biosciences U.S. Food and Drug Administration has granted priority review for Harmony Biosciences’ application for WAKIX® (pitolisant) in pediatric narcolepsy

01/24/24
Azurity Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of
Zenzedi® (dextroamphetamine sulfate tablets, USP) 30 mg Due to a Mislabeled Package During Manufacturing

12/07/23
Illuminate Hypersomnia Initiative Shines Light on What It’s Like to Live with Idiopathic Hypersomnia

12/04/23
NLS Pharmaceutics Ltd Potential Next Generation Dual Orexin Agonist for Narcolepsy in Development

11/08/23
The Sleep Consortium is partnering with organizations around the world to Illuminate Hypersomnia.

09/22/23
Harmony Biosciences STATEMENT ON U.S. FOOD & DRUG ADMINISTRATION INTERIM RESPONSE TO CITIZENS PETITION

09/07/23
Harmony Biosciences announces approval of Pitolisant/Wakix for IH.

06/06/23
Dr Luis E. Ortiz joins PWN4PWN Expert Advisory Board

05/02/23
NLS Pharmaceutics Receives Green Light from the U.S. FDA to Proceed with Phase 3 Clinical Program (AMAZE) for Quilience(R) for the treatment of Narcolepsy

03/30/23
Jazz Pharmaceuticals Expands Support of the American Heart Association to Raise Awareness of the Link Between Sleep Disorders and Heart Health

03/22/23
Avadel Pharmaceuticals Announces FDA Authorization to Import Tentatively-Approved LUMRYZ™ Ahead of Anticipated Final Approval Decision

01/03/23
Hikma launches authorized generic of Xyrem® (sodium oxybate) in the US

01/01/23
Dr Anne Marie Morse joins PWN4PWN Expert Advisory Board (follow her on instagram)

Newsroom and press releases.

More to come.